DOCSLIB.ORG

Developing Role of Short-Lived Radionuclides in Nuclear Medical Pisctice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Developing Role of Short-Lived Radionuclides in Nuclear Medical Pisctice International Copyright,0 U. S. Department of Energy, 1985, under the pro- visions of the Universal Copyright Convention. United States copyright is not asserted under the United States Copyright Law, Title 17, United States Code. Ubrary of Coagress Gitalogbg u Pafchcatioa Dsta Main entry under title: The Developing role of short-lived radionuclides in nuclear medical pisctice. (DOE symposium series ; 56) "CONF-820523 (DE8200S258)." Includes bibliographies and bdex. 1. Radiopharmaceuticals—Congresses. 2. Nuclear medicine—Congresses. I. Paras, Peter. II. Thiessen, J. W. III. United States. Dept. of Energy. Office of Health and Environmental Research. IV. Series. [DNLM: I. Nuclear Medicine—congresses. 2. Radioisotopes —congresses. WN 440 D489 1982] RS431.R34D48 1985 615.8'424 84-26718 ISBN O-87O79-518-X Available as DE82008258 (CONF-820523) for $22.25 from National Technical Information Service U. S. Department of Commerce Springfield, Virginia 22161 Printed in the United States of America March 1985 CONF-820523- DE82 008258 The Developing Role of Short-Lived Radionuclides in Nuclear Medical Practice Proceedings of a symposium held at Washington, D. C, May 3-5, 1982, in the Pan American Health Organization Building Sponsored by U. S. Department of Energy, Office of Health and Environmental Research U. S. Food and Drug Administration, Center for Devices and Radiological Health American College of Nuclear Physicians Society of Nuclear Medicine Pan American Health Organization Editors Peter Paras Center for Devices and Radiological Health and J. W. Thiessen Office of Health and Environmental Research 1985 Published by Office of Scientific and Technical Information United States Department of Energy ABOUT THE OFFICE OF SCIENTIFIC AND TECHNICAL INFORMATION The Office of Scientific and Technical Information (OSTI) in Oak Ridge. Tennessee, has been the national center for scientific and technical information for the Depart- ment of Energy (DOE) and its predecessor agencies since 1946 In developing and managing DOE's technical information program. OSTI places under bibliographic control not only DOE-onginated information but also worldwide literature on scten- tific and technical advances tn the energy field and announces the source and availability of this information Whereas the literature of science is emphasized, coverage is extended to DOE programmatic, soooeconomic. environmental, legislative/regulatory, energy analysis, and policy-related areas To accomplish this mission, OSTI builds and maintains computerized energy-information data bases and disseminates this information via computerized retneva! systems and announcement publications such as abstracting journals, bibliographies, and update journals Direct access to OSTI's most comprehensive data base, the Energy Data Base, is available to the public through commercial on-line twbliographc retrieval systems The Energy Data Base and many of OSTVs energy-related data bases are available to DOE offices and contractors and to other government agencies via DOE/RECON, the Department's on-line information retneval system The Office of Scientific and Technical Information has developed and maintains systems to record and com- municate energy-related research-m-progress information, to maintain a register of DOE public communications publications, to track research report deliverables from DOE contractors, and to test and make available DOE-funded computer software programs with scientific and management applications. OSTI also serves as adviser for special publication needs of the Department To effectively manage DOE's technical information resources. OSTI's program is one ctf continual development and evaluation of new information products, systems, and technologies UNITED STATES DEPARTMENT OF ENERGY John C. Herrington, Secretary Martha Hesse Dolan, Assistant Secretary. Management and Administration William S. Heffetfingw, Director oi Administration Joseph G. Coyne, Manager. Office of Scientific and Technical Information Mary N. HiR, Publication Editor ABOUT THE DOE SYMPOSIUM SERIES The Office of Scientific and Technical Information publishes refereeti proceedings of specially selected DOE-sponsored sym- posia. Titles in this series frequently are used as texts and refer- ence books in the disciplines covered. Preface This book contains the proceedings of the Internationa! Sym- posium on the Developing Role of Short-Lived Radionuclides (SLR's) in Nuclear Medical Practice held in Washington, D.C., May 3-5, 1982. This was the second symposium that focused mainly on the medical applications of iodine-123; the first was entitled "Applications of Iodine-123 in Nuclear Medicine" [HEW Publication (FDA) 76-8033]. Cosponsors of the symposium were the then Bureau of Radiological Health (BRH) (now the Center for Devices and Radiologi- cal Health) of the Food and Drug Administration (FDA), the Office of Health and Environmental Research of the Department of Energy (DOE), the Pan American Health Organization (PAHO), the Society of Nuclear Medicine (SNM), and the American College of Nuclear Physicians (ACNP). We are grateful to FDA and DOE for providing the financial support that made the symposium possible and to PAHO for making available their excellent facilities and support personnel for the meeting. The purpose of the symposium was to define the develop- ing role and state-of-the-art development of SLR's in current nuclear medical practice. Also, the meeting provided a forum for concerned government, industrial, and professional organizations to explore and coordinate potentials for dependable commercial supply of SLR's to medical practice through the establishment of a network of production facili- ties. Special emphasis was placed on radionuclides with general-purpose labeling capabilities. The need for high- purity labeling-grade iodine-123 was emphasized in the pro- gram. In planning the program it was thought logical to devote a series of presentations to e;-.ch of the following specific areas: History and Review of SLR Development and the Role of Sponsoring Agencies, Overview of Current SLR PREFACE Development and Utilization from Various International Venues, Present and Potential SLR Production (government, noncommercial, and commercial facilities), Uses and Label- ing with SLR's, and submitted papers of general interest. The final day was devoted to consensus panels on (1) SLR users, (2) noncommercial SLR producers, and (3) commer- cial SLR producers. Finally, a special overview summary and recommendations for present and future uses of SLR's, skillfully presentid by Dr. Henry N. Wagner, Jr., highlighted the meeting. Contained in this volume are the invited and contributed papers in the order in which they were presented. The pub- lished discussions represent efforts of the editors to record the most significant of the informal comments made at the meeting. It is hoped that the editing, performed in the inter- est of brevit-- and clarity, has not done injustice to any speaker's inu». .ons. Most of the papers and particularly the consensus panel discussions were reproduced from tape recordings. Every effort has been made to have the text cf all the papers and much of the discussion reviewed by the writer or speaker; in this regard the editors have received a great deal of assistance. Owing to the sudden illness of Dr. H. A. O'Brien, the noncommercial consensus panel was chaired by Dr. F. J. Bonte. The consensus panel discussions were edited by Dr. P. Paras, and any errors or failure to convey the meaning as intended are his responsibility. Special thanks go to Dr. William C. Eckelman and Mr. Michael L. Cianci of George Washington University, Wash- ington, D.C., who prepared the first draft of the executive summary, and to Dr. Henry N. Wellman for reviewing it. The close cooperation, patience, and assistance of Mary N. Hill, Technical Publication Editor, DOE Office of Scientific and Technical Information (OSTI), in performing the innu- merable behind-the-scenes editorial tasks is acknowledged. The excellence of this publication is the result of the skillful editorial effort of Mrs. Hiil and members of the OSTI staff (for editing, composing, graphic arts, and photography). The symposium was the result of the foresight of Dr. Peter Paras and Dr. J. W. Thisssen who recognized the need to reassess the status of iodine-123 productions for research arid clinical applications and to develop recommen- dations for convenient availability. Dr. Henry N. Wellman served as the chairman of the symposium. The program PREFACE v committee representatives of the sponsoring organizations were responsible for the final program; members of the Pro- gram Committee were. Chairman, Henry N. Wellma.n.. M.D., for ACNP; Cochairman, Vincent J. Sodd, Ph.D., for the SNM; Peter iParas, Ph.D., for FDA; J. W. Thiessen, M.D., for DOE; R. William Lambrecht, Ph.D., for the SNM; and Leonard I. Wiebe, Ph.D., for the Radiopharma- ceutical Council of the SNM. The major responsibility for planning and implementing the program was vested to Dr. Wellman and Dr. Paras, who handled the numerous behind-the-scenes tasks involved in selection and acceptance of the invited speakers who made possible the excellence of the program and this publication. A special luster was added to the meeting by the pres- ence of Dr. William G. Myers, historian of the SNM, an early leader in the use of radionuclides in medicine and in particular the first to pinpoint the usefulness of iodine-123; he has continued to contribute to research and
Load more

Recommended publications
  • Wachter-Et-Al-LSM-32(2003)101-110.Pdf
    Lasers in Surgery and Medicine 32:101–110 (2003) Topical Rose Bengal: Pre-Clinical Evaluation of Pharmacokinetics and Safety 1 1 1 1 2 Eric Wachter, PhD, * Craig Dees, PhD, Jay Harkins, Timothy Scott, PhD, Mark Petersen, DVM, 3 4 Rusty E. Rush, MS, and Amy Cada, PhD 1Provectus Pharmaceuticals, Inc., Knoxville, Tennessee 37931 2College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee 37916 3Springborn Laboratories, Inc., Spencerville, Ohio 45887 4Therimmune Research Corporation, Gaithersburg, Maryland 20879 Background and Objectives: Rose bengal (RB) is a should have minimal potential for side effects, such as potent photosensitizer that has largely been overlooked as a prolonged photosensitivity. potential photodynamic therapy (PDT) agent. In this study, Since RB readily photobleaches [29], its photodynamic the feasibility of topical delivery of RB to the epidermis has effects may be self-limiting. This is particularly relevant for been evaluated. treatment of many dermatologic conditions, such as psoria- Study Design/Materials and Methods: Topical formu- sis and actinic keratosis, since precise light dosimetry is lations of RB were assessed on murine and rabbit skin for impractical over the large surface areas typically involved pharmacokinetic properties, cutaneous toxicity, and photo- in these diseases: a PDT regimen that exhibits self-limiting sensitization. effects would avoid the need for complex light dosimetry. Results: Hydrophilic formulations (1% RB) exhibited The combination of photodynamic potential, substantial
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak Et Al
    US008343962B2 (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak et al. (45) Date of Patent: *Jan. 1, 2013 (54) TOPICAL FORMULATION (58) Field of Classi?cation Search ............. .. 514/226.5, 514/334, 420, 557, 567 (75) Inventors: Edward T. Kisak, San Diego, CA (US); See application ?le fOr Complete Search history. John M. NeWsam, La Jolla, CA (US); _ Dominic King-Smith, San Diego, CA (56) References C‘ted (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Goleta, CA (US) US' PATENT DOCUMENTS 5,602,183 A 2/1997 Martin et al. (73) Assignee: NuvoResearchOntano (CA) Inc., Mississagua, 6,328,979 2B1 12/2001 Yamashita et a1. 7,001,592 B1 2/2006 Traynor et a1. ( * ) Notice: Subject to any disclaimer, the term of this 7,795,309 B2 9/2010 Kisak eta1~ patent is extended or adjusted under 35 2002/0064524 A1 5/2002 Cevc U.S.C. 154(b) by 212 days. FOREIGN PATENT DOCUMENTS This patent is subject to a terminal dis- W0 WO 2005/009510 2/2005 claimer- OTHER PUBLICATIONS (21) APPI' NO‘, 12/848,792 International Search Report issued on Aug. 8, 2008 in application No. PCT/lB2007/0l983 (corresponding to US 7,795,309). _ Notice ofAlloWance issued on Apr. 29, 2010 by the Examiner in US. (22) Med Aug- 2’ 2010 Appl. No. 12/281,561 (US 7,795,309). _ _ _ Of?ce Action issued on Dec. 30, 2009 by the Examiner in US. Appl. (65) Prior Publication Data No, 12/281,561 (Us 7,795,309), Us 2011/0028460 A1 Feb‘ 3’ 2011 Primary Examiner * Raymond Henley, 111 Related U 5 Application Data (74) Attorney, Agent, or Firm * Foley & Lardner LLP (63) Continuation-in-part of application No.
    [Show full text]
  • Ophthalmic Herpes Zoster
    OPHTHALMIC HERPES ZOSTER RONALD J. MARSH and MATTHEW COOPER London SUMMARY Fig. 1 shows the age and sex distribution, which is A current review of ophthalmic zoster is presented biased in favour of females and compares with 50.7% including its virology, immunology, epidemiology and males, 49.3% females in another series.5 The 1981 census pathogenesis. We give our findings in 1356 patients for Greater London recorded 48% males and 52% referred to the Zoster Clinic at Moorfields Ey e Hospital, females. London. The treatment of the disease and its ocular com­ ONSET plications is discussed. There is a prodromal influenza-like illness of varying Ophthalmic herpes zoster is a disease varying in severity duration, with headache, pyrexia, malaise, depression, and from devastating, threatening life and sight, to so mild that sometimes neck stiffness, which may last up to a week it may pass unnoticed. The ophthalmic division of the fifth before the rash appears. This is shortly followed by local­ cranial nerve is affected in 7-17.5% of herpes zoster ised pain over the distribution of the ophthalmic nerve, patients. 1-5 Ocular involvement complicates approxi­ lymph node swelling in the corresponding drainage areas mately 50% of these cases and very rarely cases of maxil­ and, occasionally, a red eye. The localised pain is well lary herpes zoster,l affecting many of the tissues of the known to precede the rash by several days in some cases. globe and orbit by highly varied types of lesions. This probably represents the replication and migration We felt it would be helpful to report our experience with phase of the disease and is possibly accompanied by a lim­ the disease because the large number of cases we have ited viraemia.
    [Show full text]
  • A Comparison of Imaging Modalities for the Diagnosis of Osteomyelitis
    A comparison of imaging modalities for the diagnosis of osteomyelitis Brandon J. Smith1, Grant S. Buchanan2, Franklin D. Shuler2 Author Affiliations: 1. Joan C Edwards School of Medicine, Marshall University, Huntington, West Virginia 2. Marshall University The authors have no financial disclosures to declare and no conflicts of interest to report. Corresponding Author: Brandon J. Smith Marshall University Joan C. Edwards School of Medicine Huntington, West Virginia Email: [email protected] Abstract Osteomyelitis is an increasingly common pathology that often poses a diagnostic challenge to clinicians. Accurate and timely diagnosis is critical to preventing complications that can result in the loss of life or limb. In addition to history, physical exam, and laboratory studies, diagnostic imaging plays an essential role in the diagnostic process. This narrative review article discusses various imaging modalities employed to diagnose osteomyelitis: plain films, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, bone scintigraphy, and positron emission tomography (PET). Articles were obtained from PubMed and screened for relevance to the topic of diagnostic imaging for osteomyelitis. The authors conclude that plain films are an appropriate first step, as they may reveal osteolytic changes and can help rule out alternative pathology. MRI is often the most appropriate second study, as it is highly sensitive and can detect bone marrow changes within days of an infection. Other studies such as CT, ultrasound, and bone scintigraphy may be useful in patients who cannot undergo MRI. CT is useful for identifying necrotic bone in chronic infections. Ultrasound may be useful in children or those with sickle-cell disease. Bone scintigraphy is particularly useful for vertebral osteomyelitis.
    [Show full text]
  • Annual Report 2013-2014
    ANNUAL REPORT 2013 – 14 One Hundred and Fifth Year Indian Institute of Science Bangalore - 560 012 i ii Contents Page No Page No Preface 5.3 Departmental Seminars and IISc at a glance Colloquia 120 5.4 Visitors 120 1. The Institute 1-3 5.5 Faculty: Other Professional 1.1 Court 1 Services 121 1.2 Council 2 5.6 Outreach 121 1.3 Finance Committee 3 5.7 International Relations Cell 121 1.4 Senate 3 1.5 Faculties 3 6. Continuing Education 123-124 2. Staff 4-18 7. Sponsored Research, Scientific & 2.1 Listing 4 Industrial Consultancy 125-164 2.2 Changes 12 7.1 Centre for Sponsored Schemes 2.3 Awards/Distinctions 12 & Projects 125 7.2 Centre for Scientific & Industrial 3. Students 19-25 Consultancy 155 3.1 Admissions & On Roll 19 7.3 Intellectual Property Cell 162 3.2 SC/ST Students 19 7.4 Society for Innovation & 3.3 Scholarships/Fellowships 19 Development 163 3.4 Assistance Programme 19 7.5 Advanced Bio-residue Energy 3.5 Students Council 19 Technologies Society 164 3.6 Hostels 19 3.7 Award of Medals 19 8. Central Facilities 165-168 3.8 Placement 21 8.1 Infrastructure - Buildings 165 8.2 Activities 166 4. Research and Teaching 26-116 8.2.1 Official Language Unit 166 4.1 Research Highlights 26 8.2.2 SC/ST Cell 166 4.1.1 Biological Sciences 26 8.2.3 Counselling and Support Centre 167 4.1.2 Chemical Sciences 35 8.3 Women’s Cell 167 4.1.3 Electrical Sciences 46 8.4 Public Information Office 167 4.1.4 Mechanical Sciences 57 8.5 Alumni Association 167 4.1.5 Physical & Mathematical Sciences 75 8.6 Professional Societies 168 4.1.6 Centres under Director 91 4.2.
    [Show full text]
  • Isotope Production Potential at Sandia National Laboratories: Product, Waste, Packaging, and Transportation*
    Isotope Production Potential at Sandia National Laboratories: Product, Waste, Packaging, and Transportation* A. J. Trennel Transportation Systems Department *- *-, o / /"-~~> Sandia National Laboratories** ' J Albuquerque, NM 87185 O Q T » Abstract The U.S. Congress directed the U.S. Department of Energy to establish a domestic source of molybdenum-99, an essential isotope used in nuclear medicine and radiopharmacology. An Environmental Impact Statement for production of 99Mo at one of four candidate sites is being prepared. As one of the candidate sites, Sandia National Laboratories is developing the Isotope Production Project. Using federally approved processes and procedures now owned by the U.S. Department of Energy, and existing facilities that would be modified to meet the production requirements, the Sandia National Laboratories' Isotope Project would manufacture up to 30 percent of the U.S. market, with the capacity to meet 100 percent of the domestic need if necessary. This paper provides a brief overview of the facility, equipment, and processes required to produce isotopes. Packaging and transportation issues affecting both product and waste are addressed, and the storage and disposal of the four low-level radioactive waste types generated by the production program are considered. Recommendations for future development are provided. This work was performed at Sandia National Laboratories, Albuquerque, New Mexico, for the U.S. Department of Energy under Contract DE-AC04-94AL85000. A U.S. Department of Energy facility. DISTRPJTO OF THIS DOCUMENT IS UNLIMITED #t/f W A8 1 fcll PROJECT NEED AND BACKGROUND Nuclear medicine is an expanding segment of today's medical and pharmaceutical communities. Specific radioactive isotopes are vital, with molybdenum-99 (99Mo) being the most important medical isotope.
    [Show full text]
  • Ditellurides
    Molecules 2010, 15, 1466-1472; doi:10.3390/molecules15031466 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Article Novel Oxidative Ring Opening Reaction of 1H-Isotelluro- chromenes to Bis(o-formylstyryl) Ditellurides Haruki Sashida 1,*, Hirohito Satoh 1, Kazuo Ohyanagi 2 and Mamoru Kaname 1 1 Faculty of Pharmaceutical Sciences, Hokuriku University, Kanagawa-machi, Kanazawa 920-1181, Japan; E-Mail: [email protected] (M.K.) 2 Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan; E-Mail: [email protected] (K.O.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +81-76-229-6211; Fax: +81-76-229-2781. Received: 5 January 2010; in revised form: 2 February 2010 / Accepted: 5 March 2010 / Published: 9 March 2010 Abstract: The oxidation of 1-unsubstituted or 1-phenyl-1H-isotellurochromenes with m-chloroperbenzoic acid (mCPBA) in CHCl3 resulted in a ring opening reaction to produce as the sole products the corresponding o-formyl or benzoyl distyryl ditellurides, which were also produced by the hydrolysis of the 2-benzotelluropyrylium salts readily prepared from the parent isotellurochromene. Keywords: isotellurochromene; mCPBA oxidation; 2-benzotelluropyrylium salt; distyryl ditelluride 1. Introduction The preparation and investigation of the reactions of new tellurium-containing heterocycles have lately attracted increasing interest in the fields of both heterocyclic [1–3] and organotellurium chemistry [4–8]. We have been studying the syntheses and reactions of the novel tellurium- or selenium-containing heterocyclic compounds over the past twenty years.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Consensus Nomenclature Rules for Radiopharmaceutical Chemistry – Setting the Record Straight
    ÔØ ÅÒÙ×Ö ÔØ Consensus nomenclature rules for radiopharmaceutical chemistry – setting the record straight Heinz H. Coenen, Antony D. Gee, Michael Adam, Gunnar Antoni, Cathy S. Cutler, Yasuhisa Fujibayashi, Jae Min Jeong, Robert H. Mach, Thomas L. Mindt, Victor W. Pike, Albert D. Windhorst PII: S0969-8051(17)30318-9 DOI: doi: 10.1016/j.nucmedbio.2017.09.004 Reference: NMB 7967 To appear in: Nuclear Medicine and Biology Received date: 21 September 2017 Accepted date: 22 September 2017 Please cite this article as: Coenen Heinz H., Gee Antony D., Adam Michael, Antoni Gunnar, Cutler Cathy S., Fujibayashi Yasuhisa, Jeong Jae Min, Mach Robert H., Mindt Thomas L., Pike Victor W., Windhorst Albert D., Consensus nomenclature rules for radiopharmaceutical chemistry – setting the record straight, Nuclear Medicine and Biology (2017), doi: 10.1016/j.nucmedbio.2017.09.004 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Consensus nomenclature rules for radiopharmaceutical chemistry – setting the record straight Recommended guidelines, assembled by an international and inter- society working group after extensive consultation with peers in the wider field of nuclear chemistry and radiopharmaceutical sciences. Heinz H. Coenen1*, Antony D. Gee2*, Michael Adam3, Gunnar Antoni4, Cathy S.
    [Show full text]
  • Corneal Wound Repair After Rose Bengal and Green Light Crosslinking: Clinical and Histologic Study
    Cornea Corneal Wound Repair After Rose Bengal and Green Light Crosslinking: Clinical and Histologic Study Patricia Gallego-Munoz,˜ 1 Luc´ıa Ibares-Fr´ıas,1 Elvira Lorenzo,1 Susana Marcos,2 Pablo Perez-Merino,´ 2 Nandor Bekesi,2 Irene E. Kochevar,3 and M. Carmen Mart´ınez-Garc´ıa1 1Departamento de Biolog´ıa Celular, Histolog´ıa y Farmacolog´ıa, GIR de Tecnicas´ Opticas´ para el Diagnostico,´ Universidad de Valladolid, Valladolid, Spain 2Instituto de Optica,´ Consejo Superior de Investigaciones Cient´ıficas, Madrid, Spain 3Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States Correspondence: M. Carmen PURPOSE. To evaluate corneal wound healing after treatment with a new collagen crosslinking Mart´ınez-Garc´ıa, Departamento de protocol using rose bengal dye and green light (RGX). Biolog´ıa Celular, Histolog´ıa y Farm- acolog´ıa, Facultad de Medicina, Uni- METHODS. One cornea of 20 New Zealand rabbits was de-epithelialized (DE) in an 8-mm versidad de Valladolid, C/Ramon´ y diameter circle and, in another group (n ¼ 25), the DE corneas were then stained with 0.1% Cajal 7, 47005 Valladolid, Spain; rose bengal for 2 minutes and exposed to green light (532 nm) for 7 minutes (RGX). The mariacarmen.martinez.garcia@ contralateral eyes without treatment acted as controls. The animals were clinically followed uva.es. including fluorescein staining and pachymetry. Healing events were analyzed after euthanasia 0 Submitted: December 23, 2016 at 2, 30, and 60 days. Cell death (TUNEL assay), cell proliferation (5-bromo-2 -deoxyuridine Accepted: June 1, 2017 incorporation), and cell differentiation to myofibroblasts (a-SMA labeling) were carried out.
    [Show full text]
  • PF 44(1) Table of Contents Publish Date: November 1, 2017
    PF 44(1) Table of Contents Publish date: November 1, 2017 PROPOSED IRA: Proposed Interim Revision Announcements USP MONOGRAPHS IN-PROCESS REVISION: In-Process Revision GENERAL NOTICES FOR USP-NF General Notices to USP-NF (USP42-NF37) 1. TITLE AND REVISION 2. OFFICIAL STATUS AND LEGAL RECOGNITION 3. CONFORMANCE TO STANDARDS 4. MONOGRAPHS AND GENERAL CHAPTERS 5. MONOGRAPH COMPONENTS 6. TESTING PRACTICES AND PROCEDURES 7. TEST RESULTS 8. TERMS AND DEFINITIONS 9. PRESCRIBING AND DISPENSING 10. PRESERVATION, PACKAGING, STORAGE, AND LABELING GENERAL CHAPTERS <7> LABELING (USP42-NF37) <561> ARTICLES OF BOTANICAL ORIGIN (USP42-NF37) <1057> BIOTECHNOLOGY-DERIVED ARTICLES—TOTAL PROTEIN ASSAY (USP42-NF37) <1160> PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE (USP42-NF37) <1176> PRESCRIPTION BALANCES AND VOLUMETRIC APPARATUS USED IN COMPOUNDING (USP42- NF37) REAGENTS, INDICATORS, AND SOLUTIONS Reagent Specifications Aflatoxin B1 [NEW] (USP42-NF37) Aflatoxin B2 [NEW] (USP42-NF37) Aflatoxin G1 [NEW] (USP42-NF37) Aflatoxin G2 [NEW] (USP42-NF37) Clozapine N-Oxide [NEW] (USP42-NF37) Deuterated Ethanol [NEW] (USP42-NF37) Deuterium Chloride Solution [NEW] (USP42-NF37) Deuterium Oxide (USP42-NF37) Isobutyl Chloroformate [NEW] (USP42-NF37) PF 4x(x) Table of Contents 1 | P a g e Polyethylene Glycol 400 [NEW] (USP42-NF37) Polyethylene Glycol 4000 [NEW] (USP42-NF37) Pyridine, Anhydrous [NEW] (USP42-NF37) Trifluoroacetic Acid Ethyl Ester [NEW] (USP42-NF37) Test Solutions Citric Acid TS [NEW] (USP42-NF37) Sodium Chloride TS [NEW] (USP42-NF37) Volumetric Solutions
    [Show full text]
  • Time-Of-Flight PET Map out Goals by Joel S
    Volume 3, Issue 4 FALL 2006 pet center of excellence newsletter PET COE Board Meets with Industry Advisory Group to Time-of-Flight PET Map Out Goals By Joel S. Karp, PhD he idea to use time-of-flight (TOF) information in PET image reconstruction By James W. Fletcher, MD Twas originally proposed in the 1960s at a very early stage in the development of President, PET Center of Excellence positron imaging. By the early 1980s, fully functional TOF PET systems had been built, An inaugural meet- not long after the first conventional PET systems were completed. Why then did it take ing was held recently so long to introduce a clinical TOF PET scanner, and how does it compare to the first in Chicago between the TOF PET instruments built 25 years ago? PET Center of Excel- Time-of-Flight Theory lence Board of Directors The concept of time-of-flight means simply that for each annihilation event, we note (BOD) and the Industry the precise time that each of the coincident photons is detected and calculate the dif- Advisory Group (IAG). ference. Since the closer photon will arrive at its detector first, the difference in arrival The meeting was very times helps pin down the location of the annihilation event along the line between the James W. Fletcher well attended with rep- two detectors. resentation from a large To understand why this information is useful, we need to recall that normally in cross-section of industry. PET we collect line pair data at many angles and create tomographic images through The interaction and discussion at the con- traditional filtered back-projection or through an iterative series of back- and forward- joint morning meeting was lively and infor- projection steps.
    [Show full text]